Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics

Stock Information for null

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About null

Citizen Health Raises $30 Million to Build AI Advocate for Every Patient, Ushering in a New Era of Patient-Centered Healthcare
Labcorp Announces Winning Bid for Select Assets of Invitae
Invitae Enters into Agreement with Labcorp for Sale of Business
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance
Invitae Files for Voluntary Chapter 11 Protection; Pursues Sale Process
Invitae Completes Sale of Reproductive Health Assets to Natera
Invitae Divests Ciitizen Health Data Platform and Implements Further Cost Cuts
Invitae Reports Third Quarter 2023 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.